Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells

Cell Reports

Volumn 20, Issue 5, 2017, Pages 1017-1028

  Okada, Masahiro ^a,d   Chikuma, Shunsuke ^a   Kondo, Taisuke ^a   Hibino, Sana ^a   Machiyama, Hiroaki ^b   Yokosuka, Tadashi ^b   Nakano, Miyako ^c   Yoshimura, Akihiko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d RIKEN Center for Integrative Medical Sciences   (Japan)

Author keywords

core fucosylation; CRISPR screen; PD 1; tumor immunotherapy

Indexed keywords

CRISPR ASSOCIATED PROTEIN; FUCOSYLTRANSFERASE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN CAS9; PROTEIN FUT8; UNCLASSIFIED DRUG; GLYCOPROTEIN 6-ALPHA-L-FUCOSYLTRANSFERASE; PDCD1 PROTEIN, MOUSE; TUMOR PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; CELL SURFACE; CELLULAR IMMUNITY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; CORE FUCOSYLATION; CRISPR CAS SYSTEM; ENZYME INHIBITION; FUCOSYLATION; GENETIC IDENTIFICATION; GENETIC SCREENING; LOSS OF FUNCTION MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; GLYCOSYLATION; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; PATHOLOGY;

ANIMALS; CRISPR-CAS SYSTEMS; FUCOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GLYCOSYLATION; HUMANS; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MICE; NEOPLASM PROTEINS; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 85026879522     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2017.07.027     Document Type: Article

References (68)

1. Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubata, T., Yagita, H., Honjo, T., Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8 (1996), 765–772.
2. Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, D.E., Rosenberg, S.A., Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114 (2009), 1537–1544.
3. Anderson, A.C., Joller, N., Kuchroo, V.K., Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44 (2016), 989–1004.
4. Austin, J.W., Lu, P., Majumder, P., Ahmed, R., Boss, J.M., STAT3, STAT4, NFATc1, and CTCF regulate PD-1 through multiple novel regulatory regions in murine T cells. J. Immunol. 192 (2014), 4876–4886.
5. Bour-Jordan, H., Esensten, J.H., Martinez-Llordella, M., Penaranda, C., Stumpf, M., Bluestone, J.A., Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol. Rev. 241 (2011), 180–205.
6. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
7. Charlton, J.J., Chatzidakis, I., Tsoukatou, D., Boumpas, D.T., Garinis, G.A., Mamalaki, C., Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner. J. Immunol. 190 (2013), 6104–6114.
8. Charlton, J.J., Tsoukatou, D., Mamalaki, C., Chatzidakis, I., Programmed death 1 regulates memory phenotype CD4 T cell accumulation, inhibits expansion of the effector memory phenotype subset and modulates production of effector cytokines. PLoS ONE, 10, 2015, e0119200.
9. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
10. Chen, C.Y., Jan, Y.H., Juan, Y.H., Yang, C.J., Huang, M.S., Yu, C.J., Yang, P.C., Hsiao, M., Hsu, T.L., Wong, C.H., Fucosyltransferase 8 as a functional regulator of nonsmall cell lung cancer. Proc. Natl. Acad. Sci. USA 110 (2013), 630–635.
11. Chikuma, S., Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int. J. Clin. Oncol. 21 (2016), 448–455.
12. Chikuma, S., Terawaki, S., Hayashi, T., Nabeshima, R., Yoshida, T., Shibayama, S., Okazaki, T., Honjo, T., PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J. Immunol. 182 (2009), 6682–6689.
13. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., Zhang, F., Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
14. + T cell dysfunction during chronic infection. Immunity 40 (2014), 289–302.
15. Fujii, H., Shinzaki, S., Iijima, H., Wakamatsu, K., Iwamoto, C., Sobajima, T., Kuwahara, R., Hiyama, S., Hayashi, Y., Takamatsu, S., et al. Core fucosylation on T cells, required for activation of T-cell receptor signaling and induction of colitis in mice, is increased in patients with inflammatory bowel disease. Gastroenterology 150 (2016), 1620–1632.
16. Fukuda, T., Hashimoto, H., Okayasu, N., Kameyama, A., Onogi, H., Nakagawasai, O., Nakazawa, T., Kurosawa, T., Hao, Y., Isaji, T., et al. Alpha1,6-fucosyltransferase-deficient mice exhibit multiple behavioral abnormalities associated with a schizophrenia-like phenotype: importance of the balance between the dopamine and serotonin systems. J. Biol. Chem. 286 (2011), 18434–18443.
17. Gao, C., Maeno, T., Ota, F., Ueno, M., Korekane, H., Takamatsu, S., Shirato, K., Matsumoto, A., Kobayashi, S., Yoshida, K., et al. Sensitivity of heterozygous α1,6-fucosyltransferase knock-out mice to cigarette smoke-induced emphysema: implication of aberrant transforming growth factor-β signaling and matrix metalloproteinase gene expression. J. Biol. Chem. 287 (2012), 16699–16708.
18. Geng, F., Shi, B.Z., Yuan, Y.F., Wu, X.Z., The expression of core fucosylated E-cadherin in cancer cells and lung cancer patients: prognostic implications. Cell Res. 14 (2004), 423–433.
19. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369 (2013), 134–144.
20. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
21. Hoffmann, M., Pantazis, N., Martin, G.E., Hickling, S., Hurst, J., Meyerowitz, J., Willberg, C.B., Robinson, N., Brown, H., Fisher, M., et al., SPARTAC and CHERUB Investigators. Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection. PLoS Pathog., 12, 2016, e1005661.
22. Ihara, H., Ikeda, Y., Toma, S., Wang, X., Suzuki, T., Gu, J., Miyoshi, E., Tsukihara, T., Honke, K., Matsumoto, A., et al. Crystal structure of mammalian alpha1,6-fucosyltransferase, FUT8. Glycobiology 17 (2007), 455–466.
23. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
24. Ito, Y., Miyauchi, A., Yoshida, H., Uruno, T., Nakano, K., Takamura, Y., Miya, A., Kobayashi, K., Yokozawa, T., Matsuzuka, F., et al. Expression of alpha1,6-fucosyltransferase (FUT8) in papillary carcinoma of the thyroid: its linkage to biological aggressiveness and anaplastic transformation. Cancer Lett. 200 (2003), 167–172.
25. Kanda, Y., Imai-Nishiya, H., Kuni-Kamochi, R., Mori, K., Inoue, M., Kitajima-Miyama, K., Okazaki, A., Iida, S., Shitara, K., Satoh, M., Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. J. Biotechnol. 130 (2007), 300–310.
26. Kao, C., Oestreich, K.J., Paley, M.A., Crawford, A., Angelosanto, J.M., Ali, M.A.A., Intlekofer, A.M., Boss, J.M., Reiner, S.L., Weinmann, A.S., Wherry, E.J., Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 12 (2011), 663–671.
27. Koike-Yusa, H., Li, Y., Tan, E.P., Velasco-Herrera, Mdel.C., Yusa, K., Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32 (2014), 267–273.
28. Kubo, M., Kincaid, R.L., Webb, D.R., Ransom, J.T., The Ca2+/calmodulin-activated, phosphoprotein phosphatase calcineurin is sufficient for positive transcriptional regulation of the mouse IL-4 gene. Int. Immunol. 6 (1994), 179–188.
29. Li, W., Yu, R., Ma, B., Yang, Y., Jiao, X., Liu, Y., Cao, H., Dong, W., Liu, L., Ma, K., et al. Core fucosylation of IgG B cell receptor is required for antigen recognition and antibody production. J. Immunol. 194 (2015), 2596–2606.
30. Li, C.W., Lim, S.O., Xia, W., Lee, H.H., Chan, L.C., Kuo, C.W., Khoo, K.H., Chang, S.S., Cha, J.H., Kim, T., et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun., 7, 2016, 12632.
31. Lim, S.O., Li, C.W., Xia, W., Cha, J.H., Chan, L.C., Wu, Y., Chang, S.S., Lin, W.C., Hsu, J.M., Hsu, Y.H., et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30 (2016), 925–939.
32. Lin, D.Y.W., Tanaka, Y., Iwasaki, M., Gittis, A.G., Su, H.P., Mikami, B., Okazaki, T., Honjo, T., Minato, N., Garboczi, D.N., The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc. Natl. Acad. Sci. USA 105 (2008), 3011–3016.
33. Lu, P., Youngblood, B.A., Austin, J.W., Mohammed, A.U.R., Butler, R., Ahmed, R., Boss, J.M., Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J. Exp. Med. 211 (2014), 515–527.
34. Ma, H., Dang, Y., Wu, Y., Jia, G., Anaya, E., Zhang, J., Abraham, S., Choi, J.G., Shi, G., Qi, L., et al. A CRISPR-based screen identifies genes essential for West-Nile-virus-induced cell death. Cell Rep. 12 (2015), 673–683.
35. + T cells. Immunity 42 (2015), 265–278.
36. Matsumura, K., Higashida, K., Ishida, H., Hata, Y., Yamamoto, K., Shigeta, M., Mizuno-Horikawa, Y., Wang, X., Miyoshi, E., Gu, J., Taniguchi, N., Carbohydrate binding specificity of a fucose-specific lectin from Aspergillus oryzae: a novel probe for core fucose. J. Biol. Chem. 282 (2007), 15700–15708.
37. Muinelo-Romay, L., Vázquez-Martín, C., Villar-Portela, S., Cuevas, E., Gil-Martín, E., Fernández-Briera, A., Expression and enzyme activity of alpha(1,6)fucosyltransferase in human colorectal cancer. Int. J. Cancer 123 (2008), 641–646.
38. Noda, K., Miyoshi, E., Gu, J., Gao, C.X., Nakahara, S., Kitada, T., Honke, K., Suzuki, K., Yoshihara, H., Yoshikawa, K., et al. Relationship between elevated FX expression and increased production of GDP-L-fucose, a common donor substrate for fucosylation in human hepatocellular carcinoma and hepatoma cell lines. Cancer Res. 63 (2003), 6282–6289.
39. Oestreich, K.J., Yoon, H., Ahmed, R., Boss, J.M., NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181 (2008), 4832–4839.
40. Okada, M., Kanamori, M., Someya, K., Nakatsukasa, H., Yoshimura, A., Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells. Epigenetics Chromatin, 10, 2017, 24.
41. Okeley, N.M., Alley, S.C., Anderson, M.E., Boursalian, T.E., Burke, P.J., Emmerton, K.M., Jeffrey, S.C., Klussman, K., Law, C.L., Sussman, D., et al. Development of orally active inhibitors of protein and cellular fucosylation. Proc. Natl. Acad. Sci. USA 110 (2013), 5404–5409.
42. Osumi, D., Takahashi, M., Miyoshi, E., Yokoe, S., Lee, S.H., Noda, K., Nakamori, S., Gu, J., Ikeda, Y., Kuroki, Y., et al. Core fucosylation of E-cadherin enhances cell-cell adhesion in human colon carcinoma WiDr cells. Cancer Sci. 100 (2009), 888–895.
43. Parnas, O., Jovanovic, M., Eisenhaure, T.M., Herbst, R.H., Dixit, A., Ye, C.J., Przybylski, D., Platt, R.J., Tirosh, I., Sanjana, N.E., et al. A genome-wide CRISPR screen in primary immune cells to dissect regulatory networks. Cell 162 (2015), 675–686.
44. Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L.N., Karoly, E.D., Freeman, G.J., Petkova, V., Seth, P., et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun., 6, 2015, 6692.
45. Pauken, K.E., Wherry, E.J., Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36 (2015), 265–276.
46. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016), 1160–1165.
47. Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenberg, J.S., Kriz, A.J., Zetsche, B., Shalem, O., Wu, X., Makarova, K.S., et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520 (2015), 186–191.
48. Rillahan, C.D., Antonopoulos, A., Lefort, C.T., Sonon, R., Azadi, P., Ley, K., Dell, A., Haslam, S.M., Paulson, J.C., Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat. Chem. Biol. 8 (2012), 661–668.
49. Sander, J.D., Joung, J.K., CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol. 32 (2014), 347–355.
50. Schietinger, A., Philip, M., Krisnawan, V.E., Chiu, E.Y., Delrow, J.J., Basom, R.S., Lauer, P., Brockstedt, D.G., Knoblaugh, S.E., Hämmerling, G.J., et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45 (2016), 389–401.
51. Sen, D.R., Kaminski, J., Barnitz, R.A., Kurachi, M., Gerdemann, U., Yates, K.B., Tsao, H.W., Godec, J., LaFleur, M.W., Brown, F.D., et al. The epigenetic landscape of T cell exhaustion. Science 354 (2016), 1165–1169.
52. Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L., Root, D.E., Doench, J.G., Zhang, F., Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343 (2014), 84–87.
53. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
54. Singer, M., Wang, C., Cong, L., Marjanovic, N.D., Kowalczyk, M.S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 166 (2016), 1500–1511.e9.
55. Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J.M., Desrichard, A., Walsh, L.A., Postow, M.A., Wong, P., Ho, T.S., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371 (2014), 2189–2199.
56. Takahashi, T., Ikeda, Y., Miyoshi, E., Yaginuma, Y., Ishikawa, M., Taniguchi, N., alpha1,6fucosyltransferase is highly and specifically expressed in human ovarian serous adenocarcinomas. Int. J. Cancer 88 (2000), 914–919.
57. Taylor, A., Harker, J.A., Chanthong, K., Stevenson, P.G., Zuniga, E.I., Rudd, C.E., Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses. Immunity 44 (2016), 274–286.
58. Terawaki, S., Chikuma, S., Shibayama, S., Hayashi, T., Yoshida, T., Okazaki, T., Honjo, T., IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol. 186 (2011), 2772–2779.
59. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
60. Tzelepis, K., Koike-Yusa, H., De Braekeleer, E., Li, Y., Metzakopian, E., Dovey, O.M., Mupo, A., Grinkevich, V., Li, M., Mazan, M., et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 17 (2016), 1193–1205.
61. Voss, M., Künzel, U., Higel, F., Kuhn, P.H., Colombo, A., Fukumori, A., Haug-Kröper, M., Klier, B., Grammer, G., Seidl, A., et al. Shedding of glycan-modifying enzymes by signal peptide peptidase-like 3 (SPPL3) regulates cellular N-glycosylation. EMBO J. 33 (2014), 2890–2905.
62. Wang, X., Inoue, S., Gu, J., Miyoshi, E., Noda, K., Li, W., Mizuno-Horikawa, Y., Nakano, M., Asahi, M., Takahashi, M., et al. Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc. Natl. Acad. Sci. USA 102 (2005), 15791–15796.
63. Wang, X., Gu, J., Ihara, H., Miyoshi, E., Honke, K., Taniguchi, N., Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J. Biol. Chem. 281 (2006), 2572–2577.
64. Wang, T., Wei, J.J., Sabatini, D.M., Lander, E.S., Genetic screens in human cells using the CRISPR-Cas9 system. Science 343 (2014), 80–84.
65. Wang, Y., Fukuda, T., Isaji, T., Lu, J., Gu, W., Lee, H., Ohkubo, Y., Kamada, Y., Taniguchi, N., Miyoshi, E., et al. Loss of α1,6-fucosyltransferase suppressed liver regeneration: implication of core fucose in the regulation of growth factor receptor-mediated cellular signaling. Sci. Rep., 5, 2015, 8264.
66. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2013), 122–133.
67. Yamane-Ohnuki, N., Kinoshita, S., Inoue-Urakubo, M., Kusunoki, M., Iida, S., Nakano, R., Wakitani, M., Niwa, R., Sakurada, M., Uchida, K., et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87 (2004), 614–622.
68. Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., Saito, T., Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209 (2012), 1201–1217.